Anzeige
Mehr »
Donnerstag, 01.01.2026 - Börsentäglich über 12.000 News
SILBER-TSUNAMI: $82/Unze - PRINCE SILVER EXPANDIERT BOHRPROGRAMM NACH HISTORISCHEM PREISANSTIEG
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3LRUA | ISIN: SE0021148764 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
FIVEN ASA Chart 1 Jahr

Aktueller Chart FIVEN Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
FIVEN ASA-Investoren interessieren sich auch für diese Wertpapiere
ICL To Acquire Bartek Ingredients In Two Phase DealWASHINGTON (dpa-AFX) - ICL Group Ltd (ICL), a chemical and specialty mineral company, on Thursday announced that it has entered into a definitive agreement to acquire Bartek Ingredients Inc....
► Artikel lesen
Dividendenbekanntmachungen (02.12.2025) Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ABACUS GLOBAL MANAGEMENT INC  US00258Y1047  0,2 USD  0,1722 EUR  ABC ARBITRAGE SA  FR0004040608 - 0,1 EUR  B2GOLD CORP  CA11777Q2099  0...
► Artikel lesen
ICL Group Ltd Q3 Sales IncreaseWASHINGTON (dpa-AFX) - ICL Group Ltd (ICL) reported earnings for third quarter of $115 millionThe company's earnings came in at $115 million, or $0.09 per share. This compares with $113 million...
► Artikel lesen
ADC Therapeutics SA: ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large ...ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of...
► Artikel lesen
ADC Therapeutics SA: ADC Therapeutics to Provide Update on LOTIS-7 Clinical TrialCompany to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT)...
► Artikel lesen
ADC Therapeutics SA: ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational UpdateContinued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA®...
► Artikel lesen
CVR Partners, LP: CVR Partners Reports Second Quarter 2025 ResultsSecond quarter net income of $39 million, or $3.67 per common unit; EBITDA of $67 millionAnnounced cash distribution of $3.89 per common unit SUGAR LAND, Texas, July 30, 2025 (GLOBE NEWSWIRE) --...
► Artikel lesen